Insulin-like growth factor (IGF-1) concentrations were determined in a series of 23 children with juvenile chronic arthritis in conjunction with anthropometric assessment. When standardised z scores were used significant decreases in height and weight were shown in comparison with the normal age/sex matched means. Severe growth disturbance was seen, particularly in those with prolonged disease duration, which was independent of corticosteroid treatment, indicating disease activity itself is a major factor in the growth retardation. Eight children had low IGF-1 z scores-that is, less than -2-00 from age/sex matched mean. Low IGF-1 z scores were associated with low weight z scores but not with low height z scores. Overight growth hormone secretory profiles were determined in 10 patients, including seven with low IGF-1, and showed generaly normal secretion in all but one patient, who subsequently attained normal concentrations coincident with catch up growth. Increased pulse frequency of overnight secretion was commonly seen. Low IGF-l concentrations probably result from varying factors, particularly nutritional, but do not reflect marked endocrinological abnormalities in most patients.
Poor somatic growth is a feature of juvenile chronic arthritis, particularly in the systemic and polyarticular onset forms of the disease. In Still's description ' (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , Insulin-like growth factor 1 was measured by which were both significantly reduced in coma radioimmunoassay,'"from which a z score was parison with age matched normal growth data calculated by the same method as height/weight (height p=0 0005, weight p=0 002). Patient z scores using normal age and sex data. Seven of number 6 had spent a number of years in a eight patients with an IGF-I z score less than transit refugee camp before developing his -2-00 underwent growth hormone studies. arthritis and had probably experienced signifiThree additional patients with poor rates of cant preceding nutritional impairment. When growth were also studied. Overnight sampling this patient was excluded significant differences every 20 minutes was performed from 2200 to in height and weight z scores remained between 0800 hours and analysed for the mean growth patients values and the normal growth data. hormone secretion and the pulsatile pattern of Weight for height for age index was below 900/o secretion using the pulsar peak identification in five cases, a level indicative of nutritional algorithm program (NICHD, Bethesda/Univer-compromise. An additional six cases had z sity of California, Berkeley).'6 Clonidine stimu-scores less than --5 for height or weight, or lation (125 pg/kg) of growth hormone secretion both, and yet had normal weight for height was performed in the initial six patients studied, indexes owing to the proportional reduction in but owing to a hypotensive episode in one overall growth parameters. Skinfold and midpatient this test was discontinued for the subse-arm circumference measurements gave no quent patients. A normal clonidine stimulation additional information about nutritional status test was defined as a peak in growth hormone than that given by the weight z score in this of >20 mU/l. Growth hormone was measured patient group (data not shown). by radioim munoassay with second antibody Significantly lower z scores were found in separation using previously reported methods.'7 patients with prolonged disease duration (>4 Owing to wrist arthritis in many of the patients years) for both height (p=0-001) and weight estimation of bone age was of limited value (p=0-027), but no (b)
*Patient 1 was studied on two occasions about 12 months apart. Patients 1-7 had an insulin-like growth factor (IGF) z score less than -2-00, whereas patients [8] [9] [10] had an IGF z score greater than -2-00.
than -2-00 from the age/sex matched mean. Only three of the patients with low IGF-1 were receiving corticosteroid treatment. As a corollary, seven further patients receiving corticosteroid treatment had IGF-1 z scores between -0-46 and 2-00. Seven of the eight patients with low IGF-1 and three additional patients (Nos 8, 9, and 10) who showed poor rate of growth underwent overnight growth hormone estimation (table 2).
In comparison with previously published data from our laboratory, the overall mean growth hormone secretion of the patients with juvenile chronic arthritis (5 5 mU/l) was greater than that of children with growth hormone deficiency ([ 5 mU/l) and that of short statured children with normal growth hormone response to pharmacological stimulation (4-6 mU/l). 18 Seven of the 10 patients studied, however, had mean growth hormone secretion within the range of the growth hormone deficient group (0 39-5 5 mU/l). The mean number of pulses, 5 5 (range 3-7), was greater than previously seen in our growth clinic (unpublished observation). All six patients with juvenile chronic arthritis studied had normal response to clonidine stimulation. Patient 1, who before the onset of systemic onset juvenile chronic arthritis was growing on the 97th centile, improved in rate of growth, IGF-1 concentration, and mean growth hormone secretion as her disease state went into remission, with catch up growth being seen (figs 1 and 2). She continued to receive steroids throughout this time. Pubertal development also occurred, reflected in increased oestradiol from 44 to 181 pmol/l over this period. Overall, the IGF z scores correlated with both the height and weight z scores (IGF v height r=0 43, p=0 042; IGF v weight r=0-46, p=0028). The mean weight z score of those patients with an IGF-I z score less than -2)00 was significantly less than those greater than -2-00 (-1-79 compared with 0-41, p=0 007). The height z scores, however, failed to reach a significant difference (-1-87 compared with -0-70, p=0 065). No 
Considerable concern has evolved about the limitation of linear growth secondary to corticosteroid treatment, somewhat overshadowing the potential effect of the disease process itself. With the recognition of growth hormone secretion and subsequent IGF-1 production as the predominant hormonal stimulus to growth, studies have investigated possible abnormalities in this axis in a variety of chronic disease states-for example, Crohn's disease,'5 chronic renal failure,'9 thalassaemia major20-though no consistent abnormality has been shown.
Growth hormone secretion has been stimulated by drugs, but no abnormality has been shown in juvenile chronic arthritis irrespective of the corticosteroid regimen used-daily, alternate day, etc.2" This was confirmed in our study with those children receiving treatment on alternate days. Butenandt, however, showed improvement in rate of growth in patients with juvenile chronic arthritis during exogenous growth hormone treatment. 7 Growth hormone is secreted in a pulsatile nature, especially during sleep; abnormalities in this physiological pattern of secretion, particularly in the amplitude of the pulses, are reported in short children who have responded normally to insulin/arginine provocation ofgrowth hormone secretion. " Furthermore, low IGF-1 concentrations are also reported in such children. As low IGF-1 concentrations have been noted in systemic onset juvenile chronic arthritis8 this study aimed at determining physiological growth hormone patterns in children with low IGF-1, the hypothesis being that poor sleeping patterns due to disease may be blunting the physiological response.
We confirmed that IGF-1 may be low in patients with all disease onset subtypes and not only in those with systemic onset. No consistent growth hormone secretory abnormality was shown, however, though some patients did have low concentrations, falling within the range of growth hormone deficient patients. The increased pulse frequency that we noted may reflect disturbances of hypothalamic control of growth hormone secretion either because of abnormal sleep patterns or poor nutrition. Our sample size limited further analysis of the interaction between nutrition and growth hormone secretion. Variability of physiological growth hormone secretion with overlap between normal and growth hormone deficient children has been described.22 Furthermore, variability between consecutive periods of sampling23
shows the possible limitations in the investigation of physiological secretion. Chipman et al also studied physiological secretion in patients with polyarticular juvenile chronic arthritis, concluding that no abnormality was present as all patients had at least one peak exceeding 10 ng/ml during sleep.6 Considerable variability of 24 hour growth hormone secretion was also shown as in our study.
One patient was found to have a dramatic improvement in rate of growth concomitant with increases in both IGF-I and mean growth hormone secretion. Although pubertal development was a likely contributor, as confirmed biochemically, the improvement coincided with disease remission, and rate of growth seemed more exaggerated than would be expected for puberty alone This study does not exclude the possibility that exogenous growth hormone treatment may be of benefit in individual patients with persistendy poor rate of growth, but such an approach should only be considered after careful consideration of nutritional factors and maximum control of the disease process. 
